Adaptimmune Therapeutics
ADAP
ADAP was delisted on the 27th of October, 2025.
65 hedge funds and large institutions have $126M invested in Adaptimmune Therapeutics in 2023 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 18 increasing their positions, 17 reducing their positions, and 10 closing their positions.
6% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 17
0.59% more ownership
Funds ownership: 69.56% → 70.15% (+0.59%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less funds holding
Funds holding: 69 → 65 (-4)
24% less capital invested
Capital invested by funds: $166M → $126M (-$39.9M)
40% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 10
61% less call options, than puts
Call options by funds: $11K | Put options by funds: $28K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$1.78M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$1.37M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$1.03M |
| 4 |
JP Morgan Chase
New York
|
+$469K |
| 5 |
LFCM
Long Focus Capital Management
San Juan,
Puerto Rico
|
+$235K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$586K |
| 2 |
KHCM
Kettle Hill Capital Management
New York
|
-$382K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$332K |
| 4 |
Goldman Sachs
New York
|
-$171K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$143K |
ADAP Hedge Fund Activity: Q1 2023 in Review
65 of the 6,284 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q1 2023, worth a combined $126M — down 24% from $166M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of ADAP and 6 opened new positions — a net loss of 4 holders — while 17 trimmed existing stakes and 18 added.
The largest buyer was PFM Health Sciences, adding an estimated $1.78M. The largest seller was Renaissance Technologies, cutting an estimated $586K.
- 65 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q1 2023, down from 69 in Q4 2022.
- Funds reported $126M of Adaptimmune Therapeutics stock for Q1 2023, down 24% quarter-over-quarter.
- 6 funds opened new Adaptimmune Therapeutics positions in Q1 2023 and 10 closed out, a net change of -4 holders.
- The largest Adaptimmune Therapeutics buyer in Q1 2023 was PFM Health Sciences, an estimated $1.78M added.
- The largest Adaptimmune Therapeutics seller in Q1 2023 was Renaissance Technologies, an estimated $586K sold.
Based on aggregated 13F filings for Q1 2023.